UBS Downgrades Immunovant (IMVT) to Neutral

UBS analyst Colin Bristow downgraded Immunovant (NASDAQ: IMVT) from Buy to Neutral with a price target of $17.00 (from $38.00).

For an analyst ratings summary and ratings history on Immunovant click here. For more ratings news on Immunovant click here.

Shares of Immunovant closed at $14.46 yesterday.

You May Also Be Interested In

• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• Flux Power Holdings (FLUX) PT Lowered to $1.60 at Roth/MKM
• Morgan Stanley Downgrades oOh!media (OML:AU) to Equalweight